AZUR-1 Hits Primary Endpoint; Jemperli Rights Hearing Set for Oct 20
ANAB has more than doubled off its 52-week low of $13.858.
Summary
AnaptysBio's AZUR-1 trial met its 12-month primary endpoint, a major clinical milestone for dostarlimab monotherapy. Data will be presented at ESMO on Oct 25, 2026, with an FDA PDUFA date set for Feb 2027. Separately, the company is pursuing reversal of Jemperli rights in an Oct 20, 2026 hearing, with a judgment expected Q4 2026–Q1 2027. Jemperli royalties could exceed $390M annually by 2029, and the company plans to repay ~$299M of Sagard-linked debt in H2 2027. This follows the Q2 2026 report showing $177.3M net income driven by a $181.5M tax benefit. The positive trial result and upcoming catalysts position the stock for potential upside, though legal costs remain a headwind.
At the time of this announcement, ANAB was trading at $50.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $13.86 to $72.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.